Background: An increased risk of stroke has been found in women with early or late menarche in a cohort in the United Kingdom. It is uncertain if there is a similar increase in risk of stroke in women who experience early or late menarche in the United States. Methods: Using data from the observational component of the Women’s Health Initiative (WHI) [WHI Observational Study (OS)], we analyzed the 93,676 women aged 50-79 years, who participated in the OS over a period of 12±1 years. We compared the outcome of ischemic stroke in participants of 5 strata of age of menarche (10 years or younger, 11-12 years, 13-14 years, 15-16 years, and 17 years or older), as recorded at the baseline visit. An ordinal regression analysis was run to determine if there was a change in the risk of stroke over these strata. Results: Of the 93, 676 participants, 6067 reached menarche at 10 years of age or younger, and 965 reached menarche at 17 years of age or older. A smaller proportion of participants who developed an outcome of stroke were 10 years old or younger at menarche as compared to those who never developed stroke (6.4% vs. 6.5% p=0.85). A greater proportion of participants who developed an outcome of stroke were 11-12 years of age at menarche as compared to those who did not develop an outcome of stroke (42.8% vs. 41.3% p <.122). In the ordinal regression, there was a stronger correlation between developing a stroke and being a participant in the categories of 11- 12 years and 13-14 years of age at menarche than in the younger or older age group, respectively (0.14 and 0.103 vs 0.94 and 0.02 p=0.45). Conclusion: There is no significant increase in stroke risk in senior women in the United States who have menarche at an early (≤10 years) or late (≥17 years) age.
Background: There has been debate in the role of exogenous testosterone as a risk factor for stroke. Hormone replacement therapy (HRT) is considered a risk factor for stroke. The risk of ischemic stroke may increase when using testosterone-containing HRT. Methods: Using data from the observational component of the Women’s Health Initiative (WHI) [WHI Observational Study (OS)], we analyzed the 93,676 women aged 50-79 years, who participated in the OS over a period of 12±1 years. We compared the outcome of stroke in participants with reported use of a combination of testosterone and estrogen, estrogen alone, progesterone alone, and a combination of estrogen and progesterone, as recorded at the baseline visit. A logistic regression analysis was run to determine the odds of developing stroke. Results: Of the 93, 676 participants, 1772 used a combination of testosterone and estrogen (Estratest) HRT, 11,282 used progesterone alone, 10,808 used a combination of estrogen and progesterone, and 31,673 used estrogen alone. A smaller proportion of participants who developed an outcome of stroke had used Estratest as compared to estrogen alone or a combination of estrogen and progesterone (1.9% vs. 96.3% p=0.62). In the logistic regression, participants who had used Estratest were 1.2 times as likely to develop stroke as users of other hormone replacement therapy (OR 1.2 95%CI (0.96-1.6)), while women who had used progesterone only were 0.87 times less likely to develop stroke than users of other hormone replacement therapy (OR 0.874 95%CI (0.77-0.99)). After adjusting for confounders, the risk of developing stroke increased in users of Estratest (OR 1.25 95%CI (0.96-1.6) p=0.04), and decreased in users of progesterone only (OR 0.873 95%CI (0.77-0.99) p=0.038). Conclusion: Use of testosterone-containing HRT slightly increased the risk of stroke in women when compared to progesterone alone HRT, although this was not found to be significant. Stroke risk with Estratest may be considered to be similar to estrogen only and combination of estrogen plus progesterone HRT. Future studies are required to investigate these correlations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.